Rhenman & Partners Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Rhenman & Partners Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.4M	Buy	86,127 +4,500	+6%	+$393K	0.79%	54
2026 Q1	$6.85M	Sell	81,627 -17,000	-17%	-$984K	0.85%	49
2025 Q4	$4.06M	Sell	98,627 -75,000	-43%	-$2.91M	0.38%	69
2025 Q3	$6.83M	Buy	173,627 +47,000	+37%	+$1.2M	0.76%	45
2025 Q2	$2.36M	Hold	126,627	–	–	0.3%	68
2025 Q1	$2.3M	Buy	126,627 +12,627	+11%	+$278K	0.26%	67
2024 Q4	$2.49M	Sell	114,000 -36,000	-24%	-$926K	0.26%	75
2024 Q3	$4.11M	Buy	+150,000	New	+$4.18M	0.33%	68

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Rhenman & Partners Asset Management's DNTH Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its Dianthus Therapeutics (DNTH) stake by 5.5% in Q2 2026, buying an estimated $393K and bringing the position to 86,127 shares worth $8.4M. The position accounts for 0.79% of the portfolio, ranked #54.

Rhenman & Partners Asset Management first reported a position in DNTH in Q3 2024 and has held it in 8 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Rhenman & Partners Asset Management held 86,127 shares of Dianthus Therapeutics worth $8.4M as of Q2 2026.
Rhenman & Partners Asset Management bought 4,500 Dianthus Therapeutics shares in Q2 2026, an estimated $393K.
Dianthus Therapeutics made up 0.79% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #54 holding.
Rhenman & Partners Asset Management first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 8 quarters since.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.